JPMorgan Chase & Co. set a CHF 84 target price on Novartis (VTX:NOVN) in a report released on Wednesday, January 10th. The firm currently has a neutral rating on the stock.
A number of other research firms have also commented on NOVN. UBS Group set a CHF 78 price objective on Novartis and gave the company a neutral rating in a research note on Monday, October 23rd. Morgan Stanley set a CHF 88 price objective on Novartis and gave the company a buy rating in a research note on Friday, October 20th. Deutsche Bank set a CHF 83.50 price objective on Novartis and gave the company a neutral rating in a research note on Wednesday, October 4th. S&P Global set a CHF 87 price objective on Novartis and gave the company a neutral rating in a research note on Tuesday, October 24th. Finally, set a CHF 90 price objective on Novartis and gave the company a buy rating in a research note on Monday, October 30th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of CHF 88.13.
Novartis (VTX:NOVN) traded down CHF 1.20 during trading on Wednesday, reaching CHF 81.44. The company’s stock had a trading volume of 6,560,000 shares, compared to its average volume of 4,390,000. The firm has a market capitalization of $213,120.00 and a price-to-earnings ratio of 27.06. Novartis has a 12 month low of CHF 72.20 and a 12 month high of CHF 88.30.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/05/novartis-novn-pt-set-at-chf-84-by-jpmorgan-chase-co.html.
Novartis Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.